mTOR Ligands Direct Inhibition via Peptide Substrate Truncation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack direct and efficient inhibitors for the mammalian target of rapamycin (mTOR) activity, which is crucial for regulating cellular processes and tumor growth, with existing inhibitors like rapamycin having indirect effects and limitations.
Innovation Solution
Development of novel polypeptide ligands and polyligands that modulate mTOR activity by modifying natural substrates through truncation and amino acid substitution, and linking them to subcellular localization signals to target specific cellular locations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing inhibitors like rapamycin are used, then mTOR activity is inhibited, but the inhibition is indirect and less effective
Solution Approach 1:
The patent uses peptide ligands as intermediary molecules that bind to mTOR and prevent its interaction with natural substrates. These ligands act as mediators that directly block the kinase activity without requiring indirect mechanisms, thereby improving inhibition effectiveness while maintaining ease of application through simple peptide-based compounds
Solution Approach 2:
The invention modifies the binding parameters of mTOR by introducing peptide ligands with specific amino acid sequences that change the kinetic parameters of substrate binding. This results in direct and effective inhibition by altering the interaction parameters between mTOR and its substrates, making the inhibition mechanism both reliable and straightforward
2Reliability
If natural substrates are modified through truncation and amino acid substitution, then direct inhibition is achieved, but the complexity of ligand design increases
Solution Approach 1:
The patent extracts the essential binding motifs from natural mTOR substrates by truncating the full-length proteins to short peptide sequences (5-20 amino acids). This extraction retains the critical interaction elements needed for inhibition while removing unnecessary complexity, resulting in simple peptide ligands that achieve direct inhibition without requiring complex structural modifications
Solution Approach 2:
The invention segments the complex substrate proteins into discrete peptide motifs that can be independently designed and optimized. By dividing the substrate into functional segments (N-terminal, central, C-terminal regions with specific motifs), the patent enables modular design of peptide ligands that target specific binding sites, reducing overall design complexity while maintaining direct inhibition effectiveness
3Reliability
If polyligands are used to modulate mTOR activity, then therapeutic efficacy is improved, but the complexity of the compound increases
Solution Approach 1:
The patent merges multiple peptide ligands into polyligand structures where several monomeric units are linked together to form multimers. This combining approach enhances therapeutic efficacy by providing multiple binding sites that simultaneously interact with mTOR, thereby strengthening the inhibition effect. The modular nature of the merged units keeps the structural complexity manageable while achieving superior therapeutic outcomes
Data Source
AI summary
The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate mTOR activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands and polyligands to a cellular localization signal, epitope tag and/or a reporter. The invention also includes polynucleotides encoding the ligands and polyligands.